![Tom Wilton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tom Wilton
Corporate Officer/Principal bij
LOGICBIO THERAPEUTICS, INC.
Profiel
Tom Wilton currently works at LogicBio Therapeutics, Inc., as Chief Business Officer.
Mr. Wilton also formerly worked at Carisma Therapeutics, Inc., as Chief Business Officer from 2019 to 2025.
Mr. Wilton received his graduate degree from Brunel University, graduate degree from the University of Leeds, and undergraduate degree from the University of London.
Actieve functies van Tom Wilton
| Bedrijven | Functie | Begin |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Eerdere bekende functies van Tom Wilton
| Bedrijven | Functie | Einde |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01-04-2025 |
Opleiding van Tom Wilton
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
26
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Brunel University
 Brunel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
